Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models

Journal of Neuroscience

Volumn 34, Issue 28, 2014, Pages 9441-9454

  Games, Dora ^a   Valera, Elvira ^b   Spencer, Brian ^b   Rockenstein, Edward ^b   Mante, Michael ^b   Adame, Anthony ^b   Patrick, Christina ^b   Ubhi, Kiren ^b   Nuber, Silke ^b   Sacayon, Patricia ^a   Zago, Wagner ^a   Seubert, Peter ^a   Barbour, Robin ^a   Schenk, Dale ^a   Masliah, Eliezer ^b,c  

^a Prothena Biosciences Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calpain; Immunotherapy; Parkinson's disease; synuclein; synuclein propagation; synuclein truncation

Indexed keywords

ALPHA SYNUCLEIN; CALPAIN 1; MICROTUBULE ASSOCIATED PROTEIN 2; MONOCLONAL ANTIBODY; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; ASTROCYTOSIS; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOSIS; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOTHERAPY; INCLINED BEAM WALKING TEST; MORRIS WATER MAZE TEST; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

CALPAIN; IMMUNOTHERAPY; PARKINSON'S DISEASE; Α-SYNUCLEIN; Α-SYNUCLEIN PROPAGATION; Α-SYNUCLEIN TRUNCATION;

ALPHA-SYNUCLEIN; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; MOVEMENT DISORDERS; PARKINSONIAN DISORDERS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84903971406     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5314-13.2014     Document Type: Article

References (72)

1. Angot E., Steiner JA, Lema Tomé CM, Ekström P, Mattsson B, Björklund A, Brundin P. (2012) Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 7:e39465. CrossRef Medline
2. Bae E. J, Lee HJ, Rockenstein E, HoDH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ (2012) Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32:13454-13469. CrossRef Medline
3. Bar-On P., Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E (2008) Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem 105:1656-1667. CrossRef Medline
4. Bellucci A., Navarria L, Zaltieri M, Missale C, Spano P (2012) alpha-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. Brain Res 1432: 95-113. CrossRef Medline
5. Brundin P., Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11:301-307. CrossRef Medline
6. Chesselet M. F, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR (2012) Aprogressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics 9:297-314. CrossRef Medline
7. Choi D. H, Kim YJ, Kim YG, Joh TH, Beal MF, Kim YS (2011) Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. J Biol Chem 286:14168-14177. CrossRef Medline
8. Conway K. A, Harper JD, Lansbury PT (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4:1318-1320. CrossRef Medline
9. Crews L., Tsigelny I, Hashimoto M, Masliah E (2009) Role of synucleins in Alzheimer's disease. Neurotox Res 16:306-317. CrossRef Medline
10. Crews L., Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 5:e9313. CrossRef Medline
11. Cuervo A. M, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305:1292-1295. CrossRef Medline
12. Danzer K. M, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg C. R, McLean PJ (2012) Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 7:42. CrossRef Medline
13. Desplats P., Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E., Lee SJ (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106:13010-13015. CrossRef Medline
14. Dickson D. W (2001) Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol 14:423-432. CrossRef Medline
15. Dufty B. M, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford J. T, Feany MB, Masliah E, Rohn TT (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 170:1725-1738. CrossRef Medline
16. Fleming S. M, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet M. F (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24: 9434-9440. CrossRef Medline
17. Galvin J. E, Lee VM, Trojanowski JQ (2001) Synucleinopathies: clinical and pathological implications. Arch Neurol 58:186-190. CrossRef Medline
18. Games D., Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M., Barbour R, Schenk D, Nuber S, Masliah E (2013) Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alphasynuclein. Am J Pathol 182:940-953. CrossRef Medline
19. George J. M, Jin H, Woods WS, Clayton DF (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15:361-372. CrossRef Medline
20. Halliday G. (2007) Clinicopathological aspects of motor parkinsonism. Parkinsonism Relat Disord 13:S208-S210. CrossRef Medline
21. Hashimoto M., Masliah E (1999) Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol 9:707-720. CrossRef Medline
22. Iwai A. (2000) Properties of NACP/alpha-synuclein and its role in Alzheimer's disease. Biochim Biophys Acta 1502:95-109. CrossRef Medline
23. Iwai A., Yoshimoto M, Masliah E, Saitoh T (1995a) Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34:10139-10145. CrossRef Medline
24. Iwai A., Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. (1995b) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467-475. CrossRef Medline
25. Iwatsubo T., Yamaguchi H, Fujimuro M, Yokosawa H, Ihara Y, Trojanowski JQ, Lee VM (1996) Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol 148:1517-1529. Medline
26. Kasai T., Tokuda T, Yamaguchi N, Watanabe Y, Kametani F, Nakagawa M, Mizuno T. (2008) Cleavage of normal and pathological forms of alphasynuclein by neurosin in vitro. Neurosci Lett 436:52-56. CrossRef Medline
27. Kramer M. L, Schulz-Schaeffer WJ (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27:1405-1410. CrossRef Medline
28. Lansbury P. T Jr (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A 96:3342-3344. CrossRef Medline
29. Lashuel H. A, Overk CR, Oueslati A, Masliah E (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38-48. CrossRef Medline
30. Lee H. J, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285:9262-9272. CrossRef Medline
31. Lee S. J, Desplats P, Lee HJ, Spencer B, Masliah E (2012) Cell-to-cell transmission of α-synuclein aggregates. Methods Mol Biol 849:347-359. CrossRef Medline
32. Levesque S., Wilson B, Gregoria V, Thorpe LB, Dallas S, Polikov VS, Hong JS, Block M. L (2010) Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 133:808-821. CrossRef Medline
33. Levin J., Giese A, Boetzel K, Israel L, Högen T, Nübling G, Kretzschmar H, Lorenzl S. (2009) Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Exp Neurol 215:201-208. CrossRef Medline
34. Li W., West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jäkälä P., Hartmann T, Price DL, LeeMK (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102:2162-2167. CrossRef Medline
35. Liu C. W, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 280:22670-22678. CrossRef Medline
36. Luk K. C, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM (2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209:975-986. CrossRef Medline
37. Masliah E., Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y., Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269. CrossRef Medline
38. Masliah E., Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L. (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 98: 12245-12250. CrossRef Medline
39. Masliah E., Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P., Lee M, Goldstein J, Chilcote T, Games D, Schenk D (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46:857-868. CrossRef Medline
40. Masliah E., Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M., Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L., Buttini M, Games D, Schenk D (2011) Passive immunization reduces behavioral and neuropathological deficits in an alphasynuclein transgenic model of Lewy body disease. PLoS One 6:e19338. CrossRef Medline
41. McKeith I. G (2000) Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 18:865-902. CrossRef Medline
42. Ménard H. A, el-AmineM (1996) The calpain-calpastatin system in rheumatoid arthritis. Immunology Today 17:545-547. CrossRef Medline
43. Michell A. W, Tofaris GK, Gossage H, Tyers P, Spillantini MG, Barker RA (2007) The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant 16:461-474. CrossRef Medline
44. Mishizen-Eberz A. J, Guttmann RP, Giasson BI, Day GA 3rd, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR (2003) Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem 86:836-847. CrossRef Medline
45. Mishizen-Eberz A. J, Norris EH, Giasson BI, Hodara R, Ischiropoulos H, Lee VM, Trojanowski JQ, Lynch DR (2005) Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44:7818-7829. CrossRef Medline
46. Muntané G., Ferrer I, Martinez-Vicente M (2012) alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200:106-119. CrossRef Medline
47. Murphy D. D, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20:3214-3220. Medline
48. Murray I. V, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, Trojanowski J. Q, Lee VM (2003) Role of alpha-synuclein carboxyterminus on fibril formation in vitro. Biochemistry 42:8530-8540. CrossRef Medline
49. Nuber S., Harmuth F, Kohl Z, Adame A, Trejo M, Schönig K, Zimmermann F, Bauer C., Casadei N, Giel C, Calaminus C, Pichler BJ, Jensen PH, Müller CP, Amato D, Kornhuber J, Teismann P, Yamakado H, Takahashi R, Winkler J., Masliah E, Riess O (2013) A progressive dopaminergic phenotype associated with neurotoxic conversion of alpha-synuclein in BACtransgenic rats. Brain 136:412-432. CrossRef Medline
50. Oueslati A., Fournier M, LashuelHA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alphasynuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 183:115-145. CrossRef Medline
51. Price D. L, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, Cartier A., Spencer B, Patrick C, Desplats P, Ellisman MH, Masliah E (2010) Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy-implications for excitotoxicity. PLoS One 5:e14020. CrossRef Medline
52. Reynolds N. P, Soragni A, Rabe M, Verdes D, Liverani E, Handschin S, Riek R, Seeger S. (2011) Mechanism of membrane interaction and disruption by alpha-synuclein. J Am Chem Soc 133:19366-19375. CrossRef Medline
53. Rockenstein E., Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68:568-578. CrossRef Medline
54. Rockenstein E., Crews L, Masliah E (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev 59:1093-1102. CrossRef Medline
55. Roy S., Winton MJ, Black MM, Trojanowski JQ, Lee VM (2007) Rapid and intermittent cotransport of slow component-b proteins. J Neurosci 27: 3131-3138. CrossRef Medline
56. Sato K., Saito Y, Kawashima S (1995) Identification and characterization of membrane-bound calpains in clathrin-coated vesicles from bovine brain. Eur J Biochem 230:25-31. CrossRef Medline
57. Savica R., Grossardt BR, Bower JH, Ahlskog JE, Rocca WA (2013) Incidence and pathology of synucleinopathies and tauopathies related to Parkinsonism. JAMA Neurol 70:859-866. CrossRef Medline
58. Sevlever D., Jiang P, Yen SH (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47:9678-9687. CrossRef Medline
59. Spencer B., Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T., Masliah E (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alphasynuclein models of Parkinson's and Lewy body diseases. J Neurosci 29: 13578-13588. CrossRef Medline
60. Stefanis L. (2012) α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med 2:a009399. CrossRef Medline
61. Sung J. Y, Park SM, Lee CH, Um JW, Lee HJ, Kim J, Oh YJ, Lee ST, Paik SR, Chung K. C (2005) Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J Biol Chem 280:25216-25224. CrossRef Medline
62. Taschenberger G., Garrido M, Tereshchenko Y, Bähr M, Zweckstetter M, Kügler S. (2012) Aggregation of alphaSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol 123:671-683. CrossRef Medline
63. Tiscornia G., Singer O, Verma IM (2006) Production and purification of lentiviral vectors. Nat Protoc 1:241-245. CrossRef Medline
64. Trojanowski J. Q, Lee VM (1998) Aggregation of neurofilament and alphasynuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 55:151-152. CrossRef Medline
65. Tsigelny I. F, Sharikov Y, Miller MA, Masliah E (2008) Mechanism of alphasynuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies. Nanomedicine 4:350-357. CrossRef Medline
66. Tsigelny I. F, Sharikov Y, Wrasidlo W, Gonzalez T, Desplats PA, Crews L, Spencer B., Masliah E (2012) Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J 279: 1000-1013. CrossRef Medline
67. Ubhi K., Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, Whitney K, Masliah E. (2010) Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 30:6236-6246. CrossRef Medline
68. Uéda K., Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J., Ihara Y, Saitoh T (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90:11282-11286. CrossRef Medline
69. Valera E., Masliah E (2013) Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther 138:311-322. CrossRef Medline
70. Volpicelli-Daley L. A, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney D. F, Trojanowski JQ, Lee VM (2011) Exogenous alphasynuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:57-71. CrossRef Medline
71. Weinreb P. H, Zhen W, Poon AW, Conway KA, Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35:13709-13715. CrossRef Medline
72. Winner B., Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T., Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108:4194-4199. CrossRef Medline